---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004566"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:59:49.162720+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Lexeo Therapeutics posts updated corporate presentation; no material new information in 8-K

## Summary
- Updated corporate presentation posted on website January 13, 2025, for investor and analyst meetings.
- Presentation includes forward-looking statements on gene therapy trial plans and data timing.
- No financial results, leadership changes, or other material events disclosed in this filing.
- Risk factors from prior SEC filings are incorporated by reference.

## SEC filing metadata
- accession: 0000950170-25-004566
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017025004566/0000950170-25-004566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017025004566/lxeo-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004566
- JSON: https://secwatch.observer/filing/0000950170-25-004566.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.